Delcath Systems is trying to cash in on its drug/device combination product — the Delcath Hepatic Delivery System — for applications in oncology. Delcatch is initially focusing on treating primary and metastatic liver cancers.
Delcath is still early in its revenue-generating cycle. Analysts see it generating just $6.6 million in revenue this year, but that’s a major step up from 2012 where it likely raked in less than $0.5 million. We’ll know for sure on Wednesday when it reports. The key takeaway here is that Delcath is expected to lose half as much on a per-share basis as it did in Wednesday’s report than it did during the same quarter a year earlier.
Finally, we have Ebix Inc (NASDAQ:EBIX).
The provider of enterprise software solutions for the insurance industry recently came under fire for its accounting practices. Ebix has been here before, and the stock bounced back after refuting the latest claims that Ebix Inc (NASDAQ:EBIX) is engaged in aggressive and questionable accounting practices.
Ebix Inc (NASDAQ:EBIX) will get another chance to defend itself on Thursday when it reports what Wall Street expects to be marginally improved bottom-line results.
Wall Street sees Ebix Inc (NASDAQ:EBIX) earning $0.45 a share in Thursday’s report, narrowly besting the $0.44 a share it rang up a year earlier. The good news for investors is that Ebix Inc (NASDAQ:EBIX) has an impressive streak of beating profit projections in each of the 12 previous quarters.
Cross those fingers, but know the fundamentals
Investors in these five stocks have a right to be excited. They are all improving their financial situations. They are worthy of the gains that the market rally has bestowed upon them over the past year.
I wouldn’t be uncomfortable owning any of these companies. They’re doing the right thing, regardless of Mr. Market’s mood swings.
The expectations may be high, but these five stocks wouldn’t have it any other way.
Keep thinking ahead
The Motley Fool’s chief investment officer has selected his No. 1 stock for the next year. Find out which stock it is in the brand-new free report: “The Motley Fool’s Top Stock for 2013.” Just click here to access the report and find out the name of this under-the-radar company.
The article 5 Reasons Not to Worry This Week originally appeared on Fool.com and is written by Rick Munarriz, Munarriz.
Longtime Fool contributor Rick Munarriz owns shares of Ebix and Technology Investment Capital.. The Motley Fool recommends Ebix. The Motley Fool owns shares of Ebix. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
